ArticleJournal of thoracic disease2023

Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial).

Jun Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.